Biovista is pleased to announce that its patent application for the use of tetracyclic pyrazinoindoles has issued in the EU. This new patent (European patent No.: 2375900) has title “METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRZINOINDOLES” was issued on March 2, 2016.
Announcements
Survey of therapeutic strategies for chronic fatigue syndrome
Current therapeutic strategies for myalgic encephalomyelitis/chronic fatigue syndrome: results of an online survey A new paper co-authored by Biovista and the Solve ME/CFS Initiative has just been published. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, poorly understood disorder that causes only a small number of the approximately 2.5 million Americans to receive proper diagnosis. … Read More
viz.it in-context selling of life science products
Charlottesville, June 10, 2014 Biovista announces online environment for in-context selling of life science products Biovista announced today the availability of its viz.it solution. Aimed at reagent and life-sciences product companies viz.it integrates seamlessly with customer web sites and their online product catalogs and payment systems. Short for “visualize it”, viz.it lets scientists/researchers browse through … Read More
Biovista Featured in CHI’s InsightPharma Report on Drug Repositioning
Biovista Inc., Charlottesville, July 7, 2010: Biovista today announced that it is a featured company in InsightPharma’s report on Drug Repositioning. The report “Drug Repositioning: Extracting Added Value from Prior R&D Investments” by Dr. Hermann A.M. Mucke explains the basic issues surrounding drug repositioning as a pipeline development and/or lice cycle management strategy, covers the … Read More
Biovista delivers critical data for the CTSA Pharmaceutical Assets Portal
Charlottesville, VA, 12 February 2009 In recent years the life sciences community is seeing increasing evidence showing that drugs that have failed as a cure for one disease may hold promise for a different condition. An academic consortium led by UC Davis is now leading a collaborative effort, called the Pharmaceutical Assets Portal, to allow … Read More